Antiangiogenic drugs as a novel anticancer therapeutic strategy - Which are the more promising agents? What are the clinical developments and indications?

被引:16
作者
Gasparini, G [1 ]
机构
[1] Azienda Osped Bianchi Melacrino Morelli, Div Oncol, I-89100 Reggio Calabria, Italy
关键词
D O I
10.1016/S1040-8428(97)10001-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[No abstract available]
引用
收藏
页码:147 / 162
页数:16
相关论文
共 122 条
[91]   Reciprocal paracrine interactions between tumour cells and endothelial cells: The 'Angiogenesis progression' hypothesis [J].
Rak, J ;
Filmus, J ;
Kerbel, RS .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (14) :2438-2450
[92]  
RANSON MR, 1995, FORUM, V5, P238
[93]  
Relf M, 1997, CANCER RES, V57, P963
[94]   INTERFERON-ALPHA AND INTERFERON-BETA DOWN-REGULATE THE EXPRESSION OF BASIC FIBROBLAST GROWTH-FACTOR IN HUMAN CARCINOMAS [J].
SINGH, RK ;
GUTMAN, M ;
BUCANA, CD ;
SANCHEZ, R ;
LLANSA, N ;
FIDLER, IJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (10) :4562-4566
[95]  
STEIN CA, 1993, CANCER RES, V53, P2239
[96]  
STEIN CA, 1989, J CLIN ONCOL, V7, P449
[97]  
TALBOT DC, 1996, EUR J CANCER, V32, P2523
[98]  
TANAKA T, 1995, CANCER RES, V55, P836
[99]   Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth [J].
Tanaka, T ;
Manome, Y ;
Wen, P ;
Kufe, DW ;
Fine, HA .
NATURE MEDICINE, 1997, 3 (04) :437-442
[100]  
Taniguchi T, 1995, CLIN CANCER RES, V1, P1031